Login to Your Account

Quad PDUFA is Nigh; Approval Likely for Next HIV Blockbuster

By Jennifer Boggs
Managing Editor

Tuesday, August 21, 2012

A robust second quarter, approval of HIV drug Truvada (emtricitabine/tenofovir disoproxil fumarate) for prophylactic use and competitor setbacks that could add to its lead in the race for an all-oral hepatitis C virus regimen all contributed to an impressive summer for Gilead Sciences Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription